| Aptevo Therapeutics is a clinical-stage, research and development biotechnology company focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. Co.'s lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using Co.'s ADAPTIR modular protein technology platform. Co.'s preclinical candidate APVO442 was developed using its ADAPTIR-FLEX modular protein technology platform. The ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of improving the human immune system against cancer cells. We show 28 historical shares outstanding datapoints in our APVO shares outstanding history coverage, used to compute APVO market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing APVO market cap history over the course of time is important for investors
interested in comparing APVO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of APVO versus a peer is one thing; comparing
APVO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like APVO can fluctuate over the course of history.
With this page we aim to empower investors researching APVO by allowing them to research the APVO market cap history.